Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA045378 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA045378, RRID:AB_2679300
- Product name
- Anti-FSTL3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human FSTL3, Gene description: follistatin-like 3 (secreted glycoprotein), Alternative Gene Names: FLRG, FSRP, Validated applications: ICC, IHC, Uniprot ID: O95633, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinoma
The cytoplasmic expression of FSTL3 correlates with colorectal cancer progression, metastasis status and prognosis
FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus
Meng X, Zhao X, Zhou B, Song W, Liang Y, Liang M, Du M, Shi J, Gao Y
Journal of Cancer Research and Clinical Oncology 2024;150(1)
Journal of Cancer Research and Clinical Oncology 2024;150(1)
The cytoplasmic expression of FSTL3 correlates with colorectal cancer progression, metastasis status and prognosis
Li C, Fang C, Chan M, Chen C, Chang Y, Hsiao M
Journal of Cellular and Molecular Medicine 2023;27(5):672-686
Journal of Cellular and Molecular Medicine 2023;27(5):672-686
FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus
Duan W, Shi R, Yang F, Zhou Z, Wang L, Huang Z, Zang S
Cardiovascular Diabetology 2023;22(1)
Cardiovascular Diabetology 2023;22(1)
No comments: Submit comment
No validations: Submit validation data